We conclude that ZT-01 may be effective in restoring glucagon responses and preventing the onset of hypoglycemia in patients with T1D (Diabetes, Obesity and Metabolism)
Diabetes News
Tag: glucagon
The Role of Glucagon in Glycemic Variability in Type 1 Diabetes: A Narrative Review
There is growing evidences to illustrate the contribution of glucagon secretion to the glycemic variability in patients with T1DM, which may promote the development of new treatment strategies aiming to mitigate glycemic variability associated with aberrant glucagon secretion (Metabolic Syndrome and Obesity)
Glucagon for hypoglycaemia treatment in type 1 diabetes
As novel and stable glucagon formulations are being approved and launched on the market, new possibilities for improved hypoglycaemia rescues and new treatment approaches emerge (Diabetes/Metabolism Research and Reviews)
15-LB: Ready-to-Use Glucagon for the Prevention of Exercise-Induced Hypoglycemia during Aerobic Exercise
RTUG 150 μg maintained euglycemia during prolonged, continuous, intense aerobic exercise. (Diabetes)
Modulation of Glucagon Receptor Pharmacology by Receptor Activity-modifying Protein-2 (RAMP2)
RAMP2 regulates both ligand binding and G protein selectivity of the glucagon receptor (Journal of Biological Chemistry)
Glucagon and heart in type 2 diabetes: new perspectives
A possible explanation of the results with the DPPIV inhibitors and empagliflozin might be related to their divergent effect on glucagon levels. Due to unclear effects of glucagon like peptide 1 receptor agonists on glucagon, the possible role of this hormone in the Leader trial remains unclear (Cardiovascular Diabetology)
Glucose Variability in a 26-Week Randomized Comparison of Mealtime Treatment With Rapid-Acting Insulin Versus GLP-1 Agonist in Participants With Type 2 Diabetes at High Cardiovascular Risk
Glucacon-like peptide-1 receptor agonist and insulin reduced GV, weight, and some cardiometabolic risk markers while maintaining equivalent A1C levels versus BBI and might improve clinical outcomes in a larger trial (Diabetes Care)
Glucagon therapeutics, dawn of a new era for diabetes care
Although one can never predict that results in animals will be reproduced in humans, the available evidence suggests that type 1 and type 2 diabetic patients may expect far superior control of the metabolic abnormalities without the need for significant monitoring of glucose (Diabetes/Metabolism Research and Reviews)
Evidence of Extrapancreatic Glucagon Secretion in Man
These findings emphasize the existence of extrapancreatic glucagon (perhaps originating from the gut) in man and suggest that it may play a role in diabetes secondary to total pancreatectomy (Diabetes)
Effect of Repeated Glucagon Doses on Hepatic Glycogen in Type 1 Diabetes: Implications for a Bihormonal Closed-Loop System
Finding supports the safety of repeated glucagon delivery in the setting of a bihormonal closed-loop system (Diabetes Care)
The influence of glucagon on postprandial hyperglycaemia in children 5 years after onset of type 1 diabetes
Postprandial glucagon levels were associated with deterioration of glycaemic control and declining beta cell function in the first 5 years after diagnosis of type 1 diabetes (Diabetologia)
Early phase glucagon and insulin secretory abnormalities, but not incretin secretion, are similarly responsible for hyperglycemia after ingestion of nutrients
Disordered early phase insulin and glucagon secretions but not incretin secretion are involved in hyperglycemia after ingestion of nutrients in T2DM of even a short duration (Journal of Diabetes and Its Complications)
Glycosmedia is also available as an App: